BROADCASTS.com

b'In this Episode of the Epigenetics Podcast our guest Lucy Stead from the University of Leeds provides insight into her work on intratumor heterogeneity in Glioblastoma. In order to tackle this area she uses an holistic approach including Computational Genomics, In silico Modeling and Functional Genomics in order to test whether treatment-resistant subclones emerge in recurrent tumors, and characterize them in clinically relevant ways in multiple patients. And this is just a glimpse of what is discussed in this Episode.\\n\\xa0\\nReferences\\xa0\\nLucy F. Stead, Helene Thygesen, \\u2026 Pamela Rabbitts (2015) Using common variants to indicate cancer genes (International Journal of Cancer) DOI: 10.1002/ijc.28951\\xa0\\nCaroline Conway, Jennifer L. Graham, \\u2026 Lucy F. Stead (2015) Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq (Oncotarget) DOI: 10.18632/oncotarget.5529\\xa0\\nAlastair Droop, Alexander Bruns, \\u2026 Lucy F. Stead (2018) How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma (International Journal of Cancer) DOI: 10.1002/ijc.31184\\xa0\\nGeorgette Tanner, David R. Westhead, \\u2026 Lucy F. Stead (2019) Simulation of heterogeneous tumour genomes with HeteroGenesis and in silico whole exome sequencing (Bioinformatics (Oxford, England)) DOI: 10.1093/bioinformatics/bty1063\\xa0\\nNora Rippaus, Alexander F-Bruns, \\u2026 Lucy F. Stead (2019) JARID2 facilitates transcriptional reprogramming in glioblastoma in response to standard treatment (bioRxiv) DOI: 10.1101/649400\\n\\xa0\\nContact \\nhttps://twitter.com/activemotif \\nhttps://twitter.com/epigenetics_pod \\nhttps://www.linkedin.com/company-beta/35651/\\nhttps://www.facebook.com/ActiveMotifInc/ \\neMail: podcast@activemotif.com'